Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Gushengtang Holdings Limited ( (HK:2273) ) is now available.
Gushengtang Holdings Limited reported solid growth for the year ended December 31, 2025, with revenue rising 7.5% year-on-year to RMB3.25 billion and gross profit up 11.3% to RMB1.01 billion. The company also delivered stronger profitability, as EBITDA increased 22.7% to RMB621.9 million and net profit climbed 14.6% to RMB352.1 million, reflecting improved operating efficiency despite higher finance and other expenses.
The stronger earnings translated into total comprehensive income of RMB338.3 million, up from RMB319.5 million a year earlier, even after currency translation effects reduced other comprehensive income. The results underscore Gushengtang’s continued expansion and margin enhancement in its healthcare operations, suggesting a more resilient financial position and reinforcing its competitive standing in the medical services market ahead of the proposed amendments to its Articles of Association.
The most recent analyst rating on (HK:2273) stock is a Buy with a HK$46.00 price target. To see the full list of analyst forecasts on Gushengtang Holdings Limited stock, see the HK:2273 Stock Forecast page.
More about Gushengtang Holdings Limited
Gushengtang Holdings Limited is a Hong Kong-listed company operating in the healthcare sector, with its business centered on providing medical services and related products in mainland China. The group focuses on integrated treatment offerings and clinical services, positioning itself to capture growing demand for quality healthcare and wellness solutions in its core markets.
Average Trading Volume: 1,429,151
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.43B
For an in-depth examination of 2273 stock, go to TipRanks’ Overview page.